AbbVie Products LLC, a leading biopharmaceutical company headquartered in the United States, has established itself as a key player in the global healthcare industry since its founding in 2013. With a strong focus on immunology, oncology, neuroscience, and virology, AbbVie is renowned for its innovative therapies that address complex health challenges. The company’s flagship products, including Humira and Imbruvica, are distinguished by their unique mechanisms of action and proven efficacy, making significant impacts on patient care. AbbVie has achieved notable milestones, including strategic acquisitions and a robust pipeline of new treatments, solidifying its market position as a trusted provider of advanced medical solutions. With operations spanning North America, Europe, and beyond, AbbVie continues to drive advancements in healthcare, committed to improving patient outcomes worldwide.
How does AbbVie Products LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
AbbVie Products LLC's score of 65 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AbbVie Products LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of AbbVie Inc., any emissions data or climate commitments would be inherited from its parent company. AbbVie Inc. has made significant strides in addressing climate change, with initiatives cascaded down to AbbVie Products LLC. However, specific reduction targets or achievements for AbbVie Products LLC are not detailed. The company is aligned with industry standards and participates in various climate initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are sourced from AbbVie Inc. at a cascade level of 1. While no absolute emissions numbers are provided, AbbVie Inc. is committed to reducing its carbon footprint and enhancing sustainability practices across its operations. The absence of specific data does not diminish the company's commitment to climate action and its role within the broader corporate family focused on environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AbbVie Products LLC has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.